keyword
MENU ▼
Read by QxMD icon Read
search

Lung transplantation tacrolimus

keyword
https://read.qxmd.com/read/30739475/toxic-tacrolimus-concentrations-associated-with-intravenous-use-of-metoclopramide-in-a-lung-transplant-patient
#1
Alessio Provenzani, Natale D'alessandro, Piera Polidori
No abstract text is available yet for this article.
February 10, 2019: Annals of Pharmacotherapy
https://read.qxmd.com/read/30649317/postoperative-acute-kidney-injury-in-lung-transplant-recipients
#2
David Bennett, Antonella Fossi, Luca Marchetti, Nicola Lanzarone, Sauro Sisi, Rosa Metella Refini, Piersante Sestini, Luca Luzzi, Piero Paladini, Paola Rottoli
OBJECTIVES: Acute kidney injury (AKI) is a common postoperative complication after lung transplantation. The aim of the present study was to evaluate the incidence of AKI in lung transplant patients and its effect on patients and graft outcome in relation to degree of severity. METHODS: Data from 135 patients who underwent lung transplant in the same Italian institution were recorded retrospectively and analysed (69 unilateral and 66 bilateral lung transplants, age 51...
January 10, 2019: Interactive Cardiovascular and Thoracic Surgery
https://read.qxmd.com/read/30615259/a-randomized-trial-of-everolimus-based-quadruple-therapy-versus-standard-triple-therapy-early-after-lung-transplantation
#3
Jens Gottlieb, Claus Neurohr, Joachim Müller-Quernheim, Hubert Wirtz, Bjoern Sill, Heinrike Wilkens, Vasiliki Bessa, Christoph Knosalla, Martina Porstner, Carmen Capusan, Martin Strüber
Calcineurin inhibitor (CNI) therapy after lung transplantation increases risk of kidney failure. Early everolimus-based quadruple low CNI immunosuppression may improve renal function without compromising efficacy or safety. A prospective, randomized, open-label, 12-month multicenter trial was conducted at eight German sites. Patients 3-18 months after lung transplantation were randomized (1:1), stratified by baseline estimated glomerular filtration rate (eGFR). In the quadruple low CNI regimen, patients received everolimus (target trough level 3-5 ng/ml) with reduced CNI (tacrolimus 3-5 ng/ml or cyclosporine 25-75 ng/ml) and a cell cycle inhibitor plus prednisone...
January 7, 2019: American Journal of Transplantation
https://read.qxmd.com/read/30613674/renal-aspergillosis-in-a-liver-transplant-patient-a-case-report-and-review-of-literature
#4
Brigita Smolovic, Batric Vukcevic, Damir Muhovic, Marina Ratkovic
BACKGROUND: Aspergillosis is a frequent invasive fungal infection in liver recipients (affecting 1%-9.2% of all patients), second only to candidiasis. Significant risk factors for invasive aspergillosis in liver recipients include corticosteroid therapy, neutropenia, T-cell dysfunction, renal failure and requirement for renal replacement therapy. Aspergillus infection usually affects the lungs of liver recipients, with hematogenous dissemination occurring in 50%-60% of cases. Renal involvement is rare and is considered to occur in 0...
December 26, 2018: World Journal of Clinical Cases
https://read.qxmd.com/read/30602365/overdose-of-tacrolimus-as-the-trigger-causing-progression-of-posterior-reversible-encephalopathy-syndrome-and-subsequent-hepatic-infarction-after-liver-transplant-a-case-report
#5
Wei-Cheng Tseng, Hou-Chuan Lai, Chun-Chang Yeh, Hsiu-Lung Fan, Zhi-Fu Wu
Posterior reversible encephalopathy syndrome is a neurotoxic state accompanied by unique brain imaging patterns and neurologic abnormalities, typically associated with several complex clinical conditions such as preeclampsia/eclampsia, solid-organ transplant procedures, autoimmune diseases, and immunosuppressive agents. The detailed mechanism of posterior reversible encephalopathy syndrome is not known, and the current therapy is only supportive care. Here, we present a 33-year-old parturient woman with preeclampsia complicated with hemolysis, elevated liver enzymes, and low platelet syndrome, fulminant hepatitis B, acute fatty liver, and posterior reversible encephalopathy syndrome...
December 31, 2018: Experimental and Clinical Transplantation
https://read.qxmd.com/read/30577265/acute-cellular-rejection-and-infection-rates-in-alemtuzumab-vs-traditional-induction-therapy-agents-for-lung-and-heart-transplantation-a-systematic-review-and-meta-analysis
#6
K H C Li, J C S Ho, B Recaldin, M Gong, J Ho, G Li, T Liu, W K K Wu, M C S Wong, Y Xia, M Dong, G Tse
BACKGROUND AND OBJECTIVES: Heart and lung transplantation is a high-risk procedure, requiring intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a CD52-specific monoclonal antibody, is increasingly used for induction therapy compared with conventional agents. However, there has been no systematic review comparing its efficacy with traditional therapeutic drugs. METHODS: PubMed and EMBASE were searched to October 1, 2017, for articles on alemtuzumab in cardiothoracic transplant surgery...
December 2018: Transplantation Proceedings
https://read.qxmd.com/read/30577263/acute-cellular-rejection-and-infection-rates-in-alemtuzumab-vs-traditional-induction-therapy-agents-for-lung-and-heart-transplantation-a-systematic-review-and-meta-analysis
#7
K H C Li, J C S Ho, B Recaldin, M Gong, J Ho, G Li, T Liu, W K K Wu, M C S Wong, Y Xia, M Dong, G Tse
BACKGROUND AND OBJECTIVES: Heart and lung transplantation is a high-risk procedure requiring intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a CD52-specific monoclonal antibody, is increasingly used for induction therapy compared with conventional agents. However, there has been no systematic review comparing its efficacy with traditional therapeutic drugs. METHODS: PubMed and EMBASE were searched to October 1, 2017, for articles on alemtuzumab in cardiothoracic transplant surgery...
December 2018: Transplantation Proceedings
https://read.qxmd.com/read/30471069/comparison-of-skin-cancer-incidence-in-caucasian-and-non-caucasian-liver-vs-lung-transplant-recipients-a-tale-of-two-regimens
#8
Brandon E Cohen, Igor Krivitskiy, Sarah Bui, Kevin Forrester, Jeffrey Kahn, Richard Barbers, Binh Ngo
BACKGROUND: Organ transplantation is a significant risk factor for the development of skin cancer. The impact of skin type, immunosuppressive regimens, and photosensitizing agents requires further study. OBJECTIVE: The objective of this study was to compare skin cancer development between Caucasian and non-Caucasian transplant recipients at the University of Southern California. METHODS: We performed a retrospective chart review of lung and liver transplantations to determine the incidence of post-transplant skin cancer...
November 23, 2018: Clinical Drug Investigation
https://read.qxmd.com/read/30452335/case-260-endobronchial-posttransplantation-lymphoproliferative-disease
#9
Ryan G Short, Tina D Tailor
History A 31-year-old woman with a history of bilateral orthotopic lung transplantation performed 10 months earlier for cystic fibrosis presented for a routine follow-up appointment, with her chief symptom being a cough. The cough started approximately 1 month prior to this appointment and was minimally productive of clear to yellow phlegm. In addition to her cough, she reported increased sinus congestion and a sensation of "something in her upper chest." She denied shortness of breath, wheezing, hemoptysis, or cigarette smoking...
December 2018: Radiology
https://read.qxmd.com/read/30401394/sustained-release-tacrolimus-stabilizes-decline-of-forced-expiratory-volume-in-1-second-through-decreasing-fluctuation-of-its-trough-blood-level
#10
Y Matsuda, S Eba, F Hoshi, H Oishi, T Sado, M Noda, A Sakurada, T Watanabe, H Niikawa, M Akiba, Y Okada
BACKGROUND: Calcineurin inhibitors are a commonly used immunosuppressive drug and over 80% of lung transplant (LTx) recipients use tacrolimus. Sustained-release tacrolimus (SRT) was developed as a once-daily formulation, resulting in slower release and reduction in peak concentration compared with twice-daily immediate-release tacrolimus (IRT). Previous reports indicate that SRT may carry fewer side effects than IRT; however, the impact of SRT in bronchiolitis obliterans syndrome (BOS) after LTx is unclear...
November 2018: Transplantation Proceedings
https://read.qxmd.com/read/30401393/management-of-de-novo-mycobacterial-infection-after-lung-transplantation-without-rifampicin-case-series-of-a-single-institution
#11
H Suzuki, Y Matsuda, M Noda, H Oishi, T Watanabe, T Sado, M Yamada, T Tamada, Y Okada
BACKGROUND AND OBJECTIVES: To treat organ transplant patients with mycobacterial infection, physicians need to pay attention to interaction between drugs used against mycobacteria and immunosuppressants. The purpose of this report is to describe the clinical features of and treatment for mycobacterial infection in lung transplant (LTx) recipients. METHODS: To investigate the incidence, treatment, and outcome for mycobacterial infection, we retrospectively reviewed 100 LTx recipients in our program since 2000...
November 2018: Transplantation Proceedings
https://read.qxmd.com/read/30387865/effects-of-conversion-from-calcineurin-inhibitors-to-sirolimus-or-everolimus-on-renal-function-and-possible-mechanisms-in-liver-transplant-recipients
#12
Kai-Fan Tsai, Lung-Chih Li, Chien-Ning Hsu, Chih-Che Lin, Yu-Hung Lin, Yu-Fan Cheng, Chih-Chi Wang, Chao-Long Chen
Mammalian targets of rapamycin inhibitors (mTORIs), including sirolimus and everolimus, are used for minimizing calcineurin inhibitors after liver transplantation. However, head-to-head randomized comparisons of these 2 mTORIs are lacking. We assessed the differences in renoprotection and possible mechanisms between sirolimus and everolimus in liver transplant recipients. For this prospective cohort study, we recruited liver transplant recipients whose regimens were switched from tacrolimus to sirolimus or everolimus at a Taiwan medical center...
November 2, 2018: Journal of Clinical Pharmacology
https://read.qxmd.com/read/30373507/twice-weekly-tacrolimus-can-overcome-pharmacologic-interaction-and-help-in-the-successful-treatment-of-pulmonary-aspergillosis-in-a-liver-transplant-recipient
#13
Yu-Cheng Chiu, Meng-Hsing Ho, Teng-Wei Chen, Chung-Bao Hsieh, Hsiu-Lung Fan
Drug-drug interactions between azoles and calcineurin inhibitors can cause issues for organ transplant specialists. Clinical practice guidelines for the treatment of solid-organ transplant recipients with invasive aspergillosis infection are lacking. Here, we present a patient who developed pulmonary aspergillosis after liver transplant. The patient had prolonged treatment with echinocandin that was not effective. A drug-drug interaction between azoles and tacrolimus caused issues for the clinical physician...
October 24, 2018: Experimental and Clinical Transplantation
https://read.qxmd.com/read/30337516/clinical-outcomes-of-tuberculosis-in-recipients-after-living-donor-liver-transplantation
#14
Noruel Gerard A Salvador, Sin-Yong Wee, Chih-Che Lin, Chao-Chien Wu, Hung-I Lu, Ting-Lung Lin, Wei-Feng Lee, Yi-Chia Chan, Li-Man Lin, Chao-Long Chen
BACKGROUND This study aimed to determine clinical outcomes using various drugs during tuberculosis (TB) treatment among living donor liver transplant (LDLT) recipients with TB and to assess the impact of performing LDLT in patients with active TB at the time of LDLT. MATERIAL AND METHODS Out of 1313 LDLT performed from June 1994 to May 2016, 26 (2%) adult patients diagnosed with active TB were included in this study. Active TB was diagnosed using either TB culture, PCR, and/or tissue biopsy. RESULTS The median age was 56 years and the male/female ratio was 1...
October 19, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://read.qxmd.com/read/30326889/successful-lung-transplantation-in-an-hiv-seropositive-patient-with-desquamative-interstitial-pneumonia-a-case-report
#15
Shaun Ong, Robert D Levy, John Yee, Nilu Partovi, Andrew Churg, Philippe Roméo, Jean Chalaoui, Roland Nador, Alissa Wright, Hélène Manganas, Christopher J Ryerson
BACKGROUND: Until recently, lung transplantation was not considered in patients with human immunodeficiency virus (HIV). HIV seropositive patients with suppressed viral loads can now expect long-term survival with the advent of highly active antiretroviral therapies (HAART); however, HIV remains a relative contraindication to lung transplantation. We describe, to our knowledge, the first HIV seropositive lung transplant recipient in Canada. We also review the literature of previously reported cases of solid-organ transplantation in patients with HIV with a focus on immunosuppression considerations...
October 16, 2018: BMC Pulmonary Medicine
https://read.qxmd.com/read/30255136/liver-allograft-failure-after-nivolumab-treatment-a-case-report-with-systematic-literature-research
#16
Dimitri Gassmann, Stefan Weiler, Joachim C Mertens, Cäcilia S Reiner, Bart Vrugt, Mirjam Nägeli, Joanna Mangana, Beat Müllhaupt, Fabienne Jenni, Benjamin Misselwitz
Background: Orthotopic liver transplantation (OLT) is a potential curative treatment in patients with hepatocellular carcinoma (HCC); however, treatment options for recurrent HCC after OLT are limited. Immune checkpoint inhibitors, such as nivolumab, an inhibitor of programmed cell death protein 1, have been successfully used for metastatic HCC but data on safety of nivolumab following solid organ transplantation are limited. Methods: We report a 53-year-old woman with HCC who was treated with OLT...
August 2018: Transplantation Direct
https://read.qxmd.com/read/30230044/cutaneous-infections-by-dematiaceous-opportunistic-fungi-diagnosis-and-management-in-11-solid-organ-transplant-recipients
#17
C Ferrándiz-Pulido, M T Martin-Gomez, T Repiso, C Juárez, B Ferrer, I López-Lerma, G Aparicio, C González-Cruz, F Moreso, A Román, V García-Patos
BACKGROUND: The incidence of cutaneous infections by dematiaceous fungi is rising in our environment due to the high number of solid organ transplant recipients (SOTR). OBJECTIVE: To review our experience in the management of cutaneous phaeohyphomycoses in a Spanish reference center for dermatological care of SOTR. METHODS: Retrospective clinical, histopathological and microbiological review of all SOTR diagnosed of a phaeohyphomycosis in a 7-year period...
September 19, 2018: Mycoses
https://read.qxmd.com/read/30177108/immunosuppressive-treatment-and-its-effect-on-the-occurrence-of-pneumocystis-jiroveci-mycoplasma-pneumoniae-chlamydophila-pnemoniae-and-legionella-pneumophila-infections-colonizations-among-lung-transplant-recipients
#18
J Wojarski, M Ochman, M Latos, P Biniszkiewicz, W Karolak, E Woźniak-Grygiel, M Maruszewski, M Urlik, W Mędrala, Z Kułaczkowska, K Pyrc, S Żegleń
BACKGROUND: The aim of the study was to assess the frequency of infections caused by Pneumocystis jiroveci, Chlamydophila pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae among lung transplant recipients in the context of immunosuppression. METHODS: The study group consisted of 94 patients (37 women and 57 men; mean age 42.03 years) transplanted between 2009 and 2016 at the Silesia Center for Heart Diseases (SCCS). Immunosuppressive treatment (induction and maintenance therapy) was assessed...
September 2018: Transplantation Proceedings
https://read.qxmd.com/read/30093607/tacrolimus-granules-for-oral-suspension-as-post-transplant-immunosuppression-in-routine-medical-practice-in-france-the-optimod-study
#19
Florentine Garaix, Marc Stern, François-Xavier Lamy, Laurence Dubel, Nassim Kamar
BACKGROUND Different pharmaceutical forms of oral tacrolimus allow tailored administration. The granular formulation facilitates accurate dose adjustment of tacrolimus according to patient characteristics, such as weight, or potential concomitant drug interactions. Currently, there are no data describing the use of tacrolimus granules in transplant recipients in France. MATERIAL AND METHODS OPTIMOD was a 6-month prospective, observational multicenter study that aimed to describe patient characteristics and conditions of use of tacrolimus granules...
August 10, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://read.qxmd.com/read/30080955/safety-and-effectiveness-of-direct-acting-antivirals-for-treatment-of-hepatitis-c-virus-in-patients-with-solid-organ-transplantation
#20
Marlina Mansour, Lucas Hill, Janice Kerr
BACKGROUND: The direct acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection have sustained virologic response (SVR) rates of greater than 90% in most patients. However, data evaluating DAA use in transplant patients are limited. The goal of this study was to evaluate the effectiveness and safety of HCV treatment in this high-risk population. METHODOLOGY: This single-center retrospective study included liver, kidney, lung, and/or heart transplant patients who were treated for HCV infection with DAAs...
August 6, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
keyword
keyword
167548
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"